Journal article icon

Journal article

Liberty asthma QUEST: Phase 3 randomized, double-blind, placebo-controlled, parallel-group study to evaluate dupilumab efficacy/safety in patients with uncontrolled, moderate-to-severe asthma

Abstract:

Introduction

Dupilumab, a fully human anti-IL-4Ra monoclonal antibody, inhibits signaling of both interleukin (IL)-4 and IL-13, which are key drivers of type 2-mediated inflammation. Dupilumab is approved in the EU, USA, and other countries for the treatment of adults with inadequately controlled moderate-to-severe atopic dermatitis. Following positive phase 2 results in asthma, the phase 3 Liberty Asthma QUEST trial was initiated to provide further evidence for dupilumab efficac...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1007/s12325-018-0702-4

Authors


Expand authors...
Regeneron Pharmaceuticals, Inc More from this funder
Publisher:
Springer Publisher's website
Journal:
Advances in Therapy Journal website
Volume:
35
Issue:
5
Pages:
737-748
Publication date:
2018-05-03
Acceptance date:
2018-04-26
DOI:
EISSN:
1865-8652
ISSN:
0741-238X
Pmid:
29725983
Source identifiers:
848176
Language:
English
Keywords:
Pubs id:
pubs:848176
UUID:
uuid:48808857-bd28-4422-8395-f9bff73d8b81
Local pid:
pubs:848176
Deposit date:
2018-07-19

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP